

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/538,036	03/29/2000	Christophe P. G. Gerald	57155-D/JPW	6128
7590 06/04/2004			EXAMINER	
John P White			MURPHY, JOSEPH F	
Cooper & Dunham LLP				
1185 Avenue of the Americas			ART UNIT	PAPER NUMBER
New York, NY 10036			1646	

DATE MAILED: 06/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/538,036	GERALD ET AL.			
Office Action Summary	Examiner	Art Unit			
	Joseph F Murphy	1646			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a rep - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be till by within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDON	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 25\AA	March_2004.				
,	s action is non-final.	•			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ☐ Claim(s) 218-235 is/are pending in the application 4a) Of the above claim(s) is/are withdrates 5) ☐ Claim(s) 218-234 is/are allowed. 6) ☐ Claim(s) 235 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	wn from consideration.				
Application Papers					
9) The specification is objected to by the Examina 10) The drawing(s) filed on is/are: a) accomposed as a composition and accomposition and accomposition to the second and accomposition are declaration is objected to by the E	cepted or b) objected to by the drawing(s) be held in abeyance. Setion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority documen application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applica prity documents have been receiv nu (PCT Rule 17.2(a)).	tion No ved in this National Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:				

Application/Control Number: 09/538,036

Art Unit: 1646

DETAILED ACTION

Formal Matters

Claims 218-235 are pending and under consideration.

Response to Amendment and Arguments

Applicant's arguments filed 3/25/2004 have been fully considered but they are persuasive in part.

The rejection of claim 26 under 35 U.S.C. 112, first paragraph, because the specification, which is enabling for a full length human NPFF2 protein of SEQ ID NO: 1, does not reasonably provide enablement for a monomer with a P-S6 region which is 80% identical to human NPFF2 P-S6 region, or a monomer which specifically binds to SEQ ID NO: 1, or a human NPFF2 amino acid sequence, has been rendered moot by cancellation of the claim, and is thus withdrawn.

The rejection of claim 26 under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, has been rendered moot by cancellation of the claim, and is thus withdrawn.

The rejection of claim 26 under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, has been rendered moot by cancellation of the claim, and is thus withdrawn.

Remaining issues are set forth, infra.

Application/Control Number: 09/538,036

Art Unit: 1646

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 235 stands rejected under 35 U.S.C. 102(b) as being anticipated by Lukacs et al. (1992), for reasons of record set forth in the Office Action of December 8, 2003.

The rejection of record set forth that the Lukacs et al. reference teaches the preparation of a membrane preparation, i.e. endosomes, from CHO cells which comprise the CFTR protein.

Claim 235 is directed to a membrane preparation isolated from, *inter alia*, CHO cells. Claim 235 as written does not contain a limitation wherein the membrane preparation must comprise the encoded NPFF2 protein. Therefore, the membrane preparation of Lukacs et al. anticipates the membrane preparation of claim 235 in that it is isolated from CHO cells, and is thus identical to the instantly claimed membrane preparation.

Applicant argues that claim 235 is not anticipated by the teachings of Lukas et al. because the claim is indirectly dependent upon claim 218 that comprises the encoded NPFF2 protein.

However, while claim 235 is dependent from claims reciting a host cell comprising a vector that comprises the nucleic acid encoding the NPFF2 receptor, claim 235 does not contain a limitation wherein the membrane preparation contains the encoded NPFF2 receptor. The claim only requires that the membrane preparation is prepared from a host cell comprising a vector comprising the NPFF2 encoding nuclei acid. It is possible to prepare a membrane preparation from a host cell comprising the NPFF2 nucleic acid without the membrane preparation

Application/Control Number: 09/538,036

Art Unit: 1646

comprising the NPFF2 receptor. A membrane preparation from a CHO cell that does not comprise the NPFF2 receptor, even if the CHO cell was transfected with the NPFF2 vector and expressed the protein, is not different from a membrane preparation prepared from a cell that never comprised the NPFF2 nucleic acid. Thus claim 235 is anticipated by the Lukacs et al. preparation.

Conclusion

Claim 235 is rejected.

Claims 218-234 are allowable.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph Murphy whose telephone number is (571) 272-0877. The examiner can normally be reached Monday through Friday from 7:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (571) 272-0887.

The fax number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Joseph F. Murphy, Ph. D.

Patent Examiner Art Unit 1646 June 1, 2004 ELIZABETH KEMMERER PRIMARY EXAMINER

Elyabeth C. Kenneres